Logo
x

Search

Subscribe Now

Chronic Lymphocytic Leukemia

BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III SEQUOIA Trial for the Treatment of Chronic Lymphocytic Leukemia

BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III SEQUOIA Trial for the Treatment of Chronic Lymphocytic Leukemia

  • July 30, 2021
AbbVie Reports Results of Four-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia

AbbVie Reports Results of Four-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic L...

  • June 11, 2021
AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III Head-to-Head ELEVATE-RR Trial for Chronic Lymphocytic Leukemia

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III Head-to-Head ELEVATE-RR Trial for Chronic Lymphocytic Leukemia

  • June 7, 2021
TG Therapeutics Reports the US FDA's Acceptance of BLA for Ublituximab + Ukoniq (umbralisib) to Treat Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

TG Therapeutics Reports the US FDA's Acceptance of BLA for Ublituximab + Ukoniq (umbralisib) to Treat Chronic Lymphocytic Leukemia...

  • May 26, 2021
Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at ASCO

Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at...

  • May 20, 2021
BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III Head-to-Head APSEN Trial for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III Head-to-Head APSEN Trial for R/R Chronic Lymphocytic Leukemia or Small...

  • April 29, 2021
New Drug Designations - November 2023

    New Drug Designations - November 2023

    • December 27, 2023
    The US FDA Approves BeiGene’s Label Update for Brukinsa to Include Chronic Lymphocytic Leukemia

      The US FDA Approves BeiGene’s Label Update for Brukinsa to Include Chronic Lymphocytic Leukemia

      • December 25, 2023
      Eli Lilly’s Jaypirca Receives the US FDA Approval for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma ( CLL/SLL )

        Eli Lilly’s Jaypirca Receives the US FDA Approval for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma...

        • December 4, 2023
        BMS Reports the US FDA’s Acceptance of sBLA with Priority Review for Breyanzi (lisocabtagene maraleucel) to Treat Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

          BMS Reports the US FDA’s Acceptance of sBLA with Priority Review for Breyanzi (lisocabtagene maraleucel) to Treat Chronic Lymphocy...

          • November 10, 2023
          BeiGene’s Brukinsa (zanubrutinib) Receives the NICE Recommendation for Adult Patients with Chronic Lymphocytic Leukemia

            BeiGene’s Brukinsa (zanubrutinib) Receives the NICE Recommendation for Adult Patients with Chronic Lymphocytic Leukemia

            • October 20, 2023
            Ascentage Pharma Entered into Clinical Collaboration with AstraZeneca for Lisaftoclax + Acalabrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

              Ascentage Pharma Entered into Clinical Collaboration with AstraZeneca for Lisaftoclax + Acalabrutinib in Chronic Lymphocytic Leuke...

              • October 17, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.